Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

talquetamab × Lymphoid × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 29 Other hematologic neoplasm 3 Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1 Multiple Myeloma 1

Interventions

Rituximab 1264 Cyclophosphamide 1171 Vincristine 598 Doxorubicin 534 Etoposide 475 Prednisone 460 Cytarabine 430 fludarabine 416 Methotrexate 385 Dexamethasone 363 fludarabine phosphate 353 Lenalidomide 321 Filgrastim 311 Bendamustine Hydrochloride 248 Radiotherapy 245 venetoclax 234 ibrutinib 231 obinutuzumab 211 Melphalan 208 Peripheral Blood Stem Cell Transplantation 204 Granulocyte Colony-Stimulating Factor 183 Gemcitabine 182 Bortezomib 177 Busulfan 166 Whole-Body Irradiation 165 Mycophenolic Acid 154 Tacrolimus 136 Magnetic Resonance Spectroscopy 132 Calcium Dobesilate 130 Specimen Handling 129

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07474961 2026-03-16

BLOOD-dose

Rigshospitalet, Denmark

Phase 4 Not yet recruiting

LymphoidPlasma cell

Waldenstrom Macroglobulinemia, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡